Acute Myeloid Leukemia (AML) Clinical Trial
Official title:
A Phase I/Phase II Evaluation of Laromustine (VNP40101M), A Sulfonylhydrazine Alkylating Agent, Combined With Infusional Cytarabine in Elderly Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Verified date | August 2018 |
Source | Viron Therapeutics Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
- The purpose of the Phase I portion of this study is to evaluate the safety of this
combination of medications and to determine the appropriate dose of VNP40101M to be used
in combination with infusional cytarabine (araC) in elderly patients with Acute Myeloid
Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS).
- The purpose of the Phase II portion of the study is to evaluate the effectiveness
(overall response rate) for patients treated with VNP40101M and infusional cytarabine
induction therapy.
Status | Terminated |
Enrollment | 25 |
Est. completion date | October 2010 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of AML based on WHO criteria (greater than 20% blasts in the bone marrow or blood) excluding AML M3, acute promyelocytic leukemia OR diagnosis of high-risk MDS defined as International Prognostic Scoring System INT-2. - ECOG performance status equal to 0, 1, 2. - No prior treatment for AML with myeloablative treatment. Patients may have prior treatment with a biologic therapy. Patients with MDS or AML that has evolved from MDS could have received prior low-dose cytotoxic therapy with agents such as azacytidine or low-dose Ara C. - Ability to sign an Informed Consent according to institutional guidelines. - Patients must have the following clinical laboratory values within 24 hours prior to beginning protocol treatment: a) serum creatinine less than or equal to 2.0mg/dl. b) total bilirubin less than or equal to 2.0 mg/dl c) ALT or AST less than or equal to 5 times the upper limit of normal. Exclusion Criteria: - Uncontrolled active infection. Patients with infections who are under active treatment with antibiotics and whose infections are controlled may be entered into the study. Patients with chronic hepatitis are eligible. - Active heart disease including myocardial infarction, symptomatic coronary artery disease, arrhythmias not controlled by medication or uncontrolled congestive heart failure. - Severe pulmonary disease not controlled with medication. - Patients with serum creatinine > 2.0, serum bilirubin > 2.0. ALT or AST greater that 5 times the upper limit of normal. Patients with bilirubin or creatinine outside the acceptable levels will be considered eligible if this abnormality is clearly leukemia related and discussed with the principal's investigator prior to enrollment. - Patients concurrently receiving any other standard or investigational treatment for leukemia with the exception of hydroxyurea. - Since the formulation contains 30% ethanol, patients being treated with Antabuse (disulfiram) are excluded from the study. - Patients with APL t(15;17) - Patients with ECOG performance status of 3 or 4. - Patients should be off metronidazole (Flagyl) at least 24 hours before starting laromustine. |
Country | Name | City | State |
---|---|---|---|
United States | Weill Cornell Medical College | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Viron Therapeutics Inc | Vion Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The objectives of this study are to evaluate the safety and efficacy of VNP40101M in combination with infusional Ara C as induction therapy in elderly patients with AML or high-risk MDS evolving to AML. | Subjects will be closely monitored continuously throughout the study. | ||
Secondary | The secondary objective of this study is to evaluate this regimen for toxicities in this elderly population. | Subjects will be closely monitored continuously throughout the study. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04240002 -
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
Completed |
NCT05488613 -
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
|
||
Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT02927938 -
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
|
Phase 3 | |
Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
Recruiting |
NCT03188874 -
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
|
||
Completed |
NCT00071006 -
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04079296 -
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
|
Phase 1/Phase 2 | |
Completed |
NCT04509622 -
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
|
Phase 3 | |
Withdrawn |
NCT03699384 -
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
Completed |
NCT02252107 -
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
|
Phase 2 | |
Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
Terminated |
NCT01463410 -
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
|
N/A | |
Completed |
NCT01242774 -
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT02134782 -
Yoga Fatigue Study
|
N/A | |
Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
Completed |
NCT03625505 -
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT04266795 -
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
|
Phase 2 |